Loading
Loading
Research Overview
Potent synthetic GHRP that activates GHS-R1a receptors; also demonstrated cardioprotective properties in preclinical models via CD36 receptor binding, independently of its GH-releasing action.
Overview
Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide designed to potently stimulate growth hormone secretion through activation of the ghrelin receptor (GHSR-1a) in the pituitary gland and hypothalamus. Preclinical research has characterised its pharmacological profile across both pituitary GH-releasing activity and cardiovascular tissue effects mediated through CD36 receptor engagement.
A distinctive feature of hexarelin's preclinical research profile is its ability to engage CD36, a multifunctional scavenger receptor expressed in cardiac tissue, independent of its ghrelin receptor activity. Preclinical cardiovascular studies have used hexarelin as a pharmacological tool to study CD36 biology in cardiac cells and animal models of cardiac function.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, hexarelin (ghrp-6 analogue) has no TGA approval for therapeutic use. It is sold by Capital Precision Labs strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Potent synthetic GHRP that activates GHS-R1a receptors; also demonstrated cardioprotective properties in preclinical models via CD36 receptor binding, independently of its GH-releasing action.
Support
For research use only. Capital Precision Labs products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
